

and operate them as supermarkets, Stop & Shop and SSC Associates may divest the stores to no more than two acquirers. If Stop & Shop and SSC Associates fail to satisfy any of the divestiture provisions, the Commission may appoint a trustee to divest supermarkets to satisfy the terms of the order. The 17 supermarkets to be divested are:

1. The following supermarkets located in Barnstable County, Massachusetts (a/k/a Cape Cod):

a. Purity store no. 67 located at 137 Main St. (Route 28—Falmouth Mall), Falmouth, MA 02540;

b. Purity store no. 79 located at Mashpee Circle (Routes 28 and 151—Mashpee Commons Shopping Center), Mashpee, MA 02649;

c. Purity store no. 63 located at 625 West Main St., Hyannis, MA 02601;

d. Purity store no. 72 located at 1070 Iyanough Road (Route 132), Hyannis, MA 02601;

e. Purity Store no. 66 located at 1080 State Road (Route 28 and Forest Street), Yarmouth, MA 02664;

f. Purity store no. 65 located at 18 Sisson Road, Harwich, MA 02671; and

g. Purity store no. 86 located at Cranberry Highway (Route 6A) and West Road, Orleans, MA 02653.

2. The following supermarkets located in Plymouth County, Massachusetts:

a. Purity store no. 89 located at 182 Summer St. (Routes 3A and 53—Kingsbury Square Shopping Center), Kingston, MA 02364;

b. Purity store no. 74 located at Ocean and Webster Sts. (Routes 139 and 3A—Webster Square), Marshfield, MA 02050; and

c. Purity store no. 25 located at 240 East Ashland St. (Cary Hill Shopping Center), Brockton, MA 02402.

3. The following supermarket located in Suffolk County and in the city of Boston, Massachusetts:

a. Purity store no. 41 located at 630 American Legion Highway, Roslindale, MA 02131.

4. The following supermarkets located in Middlesex County, Massachusetts:

a. Purity store no. 03 located at 170 Great Road (Routes 4 and 225), Bedford, MA 01730;

b. Purity store no. 44 located at 2151 Mystic Valley Parkway, Medford, MA 02155; and

c. Stop & Shop store no. 436 located at 550 Arsenal Street (Watertown Mall), Watertown, MA 02172.

5. The following supermarket located in Essex County, Massachusetts:

a. Purity store no. 01 located at 400 Lynn Fells Parkway, Saugus, MA 01960.

6. The following supermarkets located in Norfolk County, Massachusetts:

a. Purity store no. 20 located at 525 Harvard St., Brookline, MA 02146; and

b. Purity store no. 24 located at 10 Pleasant Valley Street, South Weymouth, MA 02190.

For a period of ten years from the date the order becomes final, the order also prohibits Stop & Shop and SSC Associates from acquiring, without prior notice to the Commission, supermarket assets located in, or any interest (such as stock) in any entity that owns or operates a supermarket located in Eastern Massachusetts. Eastern Massachusetts consists of the counties of Barnstable, Bristol, Essex, Middlesex, Norfolk, Plymouth, and Suffolk, and all cities and towns therein. This provision does not prevent Stop & Shop and SSC Associates from constructing new supermarket facilities on their own; nor does it prevent Stop & Shop and SSC Associates from leasing facilities not operated as supermarkets within the previous six months.

For a period of ten years, the order prohibits Stop & Shop and SSC Associates from entering into or enforcing any agreement that restricts the ability of any person acquiring any location used as a supermarket, or interest in any location used as a supermarket on or after July 1, 1995, to operate a supermarket at that site if that site was a former Purity store in Eastern Massachusetts, and any supermarket owned or operated by any Stop & Shop and SSC Associates either in Cape Cod or not more than two miles from any other supermarket formerly owned or operated by Purity in Eastern Massachusetts. There is an exception for agreements that impose restrictions on supermarkets that are located no more than one mile from a new replacement supermarket owned and operated by Stop & Shop or SSC Associates when the restrictions are entered into within six months of the opening of the new replacement store. In addition, Stop & Shop and SSC Associates may not remove any equipment from a supermarket they own or operate prior to a sale, sublease, assignment, or change in occupancy, except in the ordinary course of business or certain other circumstances.

Stop & Shop and SSC Associates are required to provide to the Commission a report of compliance with the order within sixty (60) days following the date the order becomes final, every sixty (60) days thereafter until the divestitures are completed, and annually for a period of ten years.

Stop & Shop and SSC Associates also entered into an Asset Maintenance Agreement. Under the terms of the Asset Maintenance Agreement, from the time

Stop & Shop and SSC Associates acquire the assets of Purity that must be divested until the divestitures set out in the attached consent agreement have been completed, Stop & Shop and SSC Associates must maintain their viability, competitiveness and marketability, must not cause their wasting or deterioration, and cannot sell, transfer, or otherwise impair their marketability or viability.

The purpose of this analysis is to invite public comment on the proposed consent order to aid the Commission in its determination of whether it should make final the proposed consent order contained in the agreement.

This analysis is not intended to constitute an official interpretation of the agreement and proposed consent order, nor is it intended to modify the terms of the agreement and proposed consent order in any way.

By direction of the Commission.

Donald S. Clark,
Secretary.

Statement of Commissioner Mary L. Azcuenaga Concurring in Part and Dissenting in Part in The Stop & Shop Companies, Inc., File No. 951-0086

I concur in the Commission's decision to accept a proposed consent order for public comment to the extent that the order requires divestiture of supermarkets on Cape Cod and the South Shore, but dissent to the extent that the order requires divestiture of stores in the Boston metropolitan area. Although serious questions can be raised about some of the allegations in the complaint that relate to the product market, I find reason to believe that the law has been violated even if the product market includes sales of food and groceries in stores other than traditional supermarkets. Assuming either the product market alleged in the complaint or a broader product market, I concur in the decision to accept the order as to Cape Cod and South Shore. I dissent from the decision to require divestiture of stores in the Boston metropolitan area. Although a small geographic market theoretically may exist within a broad metropolitan area, at this time the record before the Commission does not contain sufficient evidence to support a finding of reason to believe that the communities of Saugus, Medford, Brookline, Roslindale, Watertown, Weymouth, Brockton and Bedford, Massachusetts are relevant antitrust markets.

[FR Doc. 95-27685 Filed 11-7-95; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Office of the Secretary****Proposed Data Collections Available for Public Comment and Recommendations**

The Department of Health and Human Services, Office of the Secretary will periodically publish summaries of proposed information collections projects and solicit public comments in compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995. To request more information on the project or to obtain a copy of the information collection plans and instruments, call the OS Reports Clearance Officer on (202) 619-1053.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Project 1. 42 CFR 50 Subpart B: Sterilization of Persons in Federally Assisted Family Planning Projects—0937-0166—Extension no Change—These regulations and informed consent procedures are associated with Federally-funded sterilization services. Selected consent forms are audited during site visits and program reviews to ensure compliance with regulations and the protection of the rights of individuals undergoing sterilization. Burden Estimate for Consent Form—Annual Responses: 40,000; Burden per Response: one hour; Total Burden for Consent Form: 40,000 hours—Burden Estimate for Recordkeeping Requirement—Number of Recordkeepers: 4,000; Average Burden per Recordkeeper: 2.5 hours; Total Burden for Recordkeeping: 10,000 hours. Total Burden: 50,000 hours.

Send comments to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue SW., Washington, DC, 20201. Written comments should be received within 60 days of this notice.

Dated: October 31, 1995.
Dennis P. Williams,
Deputy Assistant Secretary, Budget.
[FR Doc. 95-27614 Filed 11-7-95; 8:45 am]
BILLING CODE 4150-04-M

Food and Drug Administration**Advisory Committee Meetings; Amendment of Notice**

AGENCY: Food and Drug Administration, HHS.

ACTION: Action.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. The meeting was announced in the Federal Register of October 20, 1995 (60 FR 54233). The amendment is being made to remove probucol, new drug application (NDA) 17-535 (Lorelco®, Hoechst Marion Roussel) for a lipid altering indication from the agenda, and change the time schedule. There are no other changes. This amendment will be announced at the beginning of the open portion of the meeting.

FOR FURTHER INFORMATION CONTACT: Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Endocrinologic and Metabolic Drugs Advisory Committee, code 12536.

SUPPLEMENTARY INFORMATION: In the Federal Register of October 20, 1995, FDA announced that a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee would be held on November 16 and 17, 1995.

On page 54233, in the first column, the "Date, time, and place" and the "Type of meeting and contact person" portions of this meeting are amended, and in the second column, the "Open committee discussion" portion of the meeting is amended to read as follows:

Date, time, and place. November 16, 1995, 1 p.m., and November 17, 1995, 8 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person. Open public hearing, November 16, 1995, 1 p.m. to 1:30 p.m., unless public participation does not last that long; open committee discussion, 1:30 p.m. and 6 p.m.; open public hearing, November 17, 1995, 8 a.m. to 8:30 a.m., unless public participation does not last that long; open committee discussion,

8:30 a.m. to 2 p.m.; Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, FAX 301-443-0699, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Endocrinologic and Metabolic Drugs Advisory Committee, code 12536.

Open committee discussion. On November 16, 1995, the committee will hear presentations and discuss data submitted regarding the safety and efficacy of dexfenfluramine hydrochloride, NDA 20-344 (Redux®, Interneuron Pharmaceuticals, Inc.), for an obesity indication, as followup to the meeting of September 28, 1995. On November 17, 1995, the committee will hear presentations and discuss data submitted regarding the safety and efficacy of sodium fluoride USP, NDA 19-975 (Slow Fluoride®, Texas Southwest Medical Center), for an osteoporosis indication.

Dated: November 2, 1995.
David A. Kessler,
Commissioner of Food and Drugs.
[FR Doc. 95-27616 Filed 11-7-95; 8:45 am]
BILLING CODE 4160-01-M

National Institutes of Health**Notice of Meeting; AIDS Research Program Evaluation Working Group**

Notice is hereby given of the meeting of the NIH AIDS Research Program Evaluation Working Group Area Review Panel on Drug Discovery on November 29-30, 1995 at the Doubletree Hotel at Lincoln Center, 5410 LBJ Freeway, Dallas, Texas 75240. The meeting will be open to the public from 9:00 am to 12:00 pm on November 29, and the closed portion will be from 1:00 pm to 6:00 pm on November 29, and 7:00 a.m. to 10:30 am on November 30.

The NIH Revitalization Act of 1993 authorizes the Office of AIDS Research (OAR) to evaluate the AIDS research activities of NIH. The NIH AIDS Research Program Evaluation Working Group was established by the OAR to carry out this major evaluation initiative, reviewing and assessing each of the components of the NIH AIDS research endeavor to determine whether those components are appropriately designed and coordinated to answer the critical scientific questions to lead to better treatments, preventions, and a cure for AIDS. Six Area Review Panels were also established to address the following research areas: Natural History and Epidemiology; Etiology and